内脏脂肪素对人血管内皮细胞MMP-1、TIMP-1及ICAM-1表达的影响
|
摘要
背景：
动脉粥样硬化(atherosclerosis, AS)是各种心脑血管疾病最重要的危险因素,随着人民生活水平的提高及饮食结构的改变,肥胖以及与肥胖相关的疾病如糖尿病、高血压及高脂血症等的发病率也逐渐增加,并通过多种机制介导着AS的形成与发展。近年来的研究证明,肥胖患者体内过量的脂肪组织分泌的多种细胞因子在AS的发生中发挥着重要的作用。
内脏脂肪素(visfatin)是新发现的一种脂肪细胞因子,不仅与多种炎症疾病有关,还参与调节多种炎症因子的合成与分泌,能够促进单核细胞表达内皮细胞粘附分子1(ICAM-1)和内皮细胞表达血管内皮生长因子(VEGF)。已有研究发现内脏脂肪素在颈动脉和冠状动脉粥样硬化斑块中显著表达。提示内脏脂肪素可能作为炎症介质参与了动脉粥样硬化的发生和发展。基质金属蛋白酶1(MMP-1)及基质金属蛋白酶抑制物1(TIMP-1)和ICAM-1在炎症所致的内皮细胞损伤中具有重要的作用。
目的：
本研究通过观察不同浓度的内脏脂肪素对血管内皮细胞(vein endothelia cell, VEC) MMP-1、TIMP-1及ICAM-1基因表达的影响,在基因表达水平探讨内脏脂肪素损伤血管内皮细胞功能,诱发动脉粥样硬化和斑块破裂的相关机制。
研究方法：
采用体外培养人脐静脉内皮细胞(HUVEC)株,将传至3-6代时处于对数生长期的细胞作为研究对象。分别用浓度为100ng/ml、200ng/ml、400ng/ml、800ng/ml的内脏脂肪素干预细胞24小时,用Trizol法提取细胞总RNA,采用逆转录-聚合酶链反应(RT-PCR)技术半定量检测不同浓度内脏脂肪素刺激后内皮细胞MMP-1、TIMP-1和ICAM-1mRNA的表达。
结果：
(1)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的MMP-1mRNA显著增多,且呈浓度依赖性。
(2)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的TIMP-1mRNA呈浓度依赖性下降,MMP-1/TIMP-1比值随内脏脂肪素干预浓度的增高而逐渐升高。
(3)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的ICAM-1mRNA水平显著升高,且其浓度越高,刺激内皮细胞表达ICAM-1mRNA的作用就越强。
结论：
(1)内脏脂肪素能够促进体外培养的人血管内皮细胞表达MMP-1,下调TIMP-1的表达,且呈剂量依赖性,MMP-1/TIMP-1的比例失衡,打破了细胞外基质合成与降解的平衡状态。
(2)内脏脂肪素促进了体外培养的人血管内皮细胞表达ICAM-1,并随着内脏脂肪素浓度的升高而表达增高,呈现剂量依赖性。
(3)内脏脂肪素可能作为炎症因子通过影响人血管内皮细胞MMP-1、TIMP-1及ICAM-1的表达参与了动脉粥样硬化性疾病的发生和发展。
Background:
As we know that atherosclerosis is the most important risk factor of cardiovascular and cardio-cerebrovascular disease. With the improvement of living standards and changing of eating habits, the incidence of obesity and obesity-related diseases such as diabetes, hypertension and hyperlipemia has gradually increased, and these diseases affect on the formation and development of atherosclerosis through various mechanisms. Recent studies have shown that several cytokines secreted by excess adipose tissue of obesity play an important role in the occurrence of atherosclerosis.
Visfatin is the most recently identified adipocytokine(known previously as pre-B cell colony enhancing factor, PBEF).Visfatin has not only associated with a variety of inflammatory diseases,but also can regulate the synthesis and secretion of inflammatory cytokine,stimulate the monoeyte releasing intereellular adhesion moleeule-1 and the endothelium releasing vascular endothelium growth factor. It has been found that visfatin expressed in carotid endarterectomy specimens and coronary artery plaques. This indicates that visfatin is not only an cytokine but also interact with atherosclerosis. MMP-1,TIMP-1 and ICAM-1 play an important role in the inflammation-induced endothelial cell injury.
Objective:
To investigate the mechanism of artherosclerosis and plaque disurptioninduced by dysfunction of vascular endothelial cell with visfatin in different concentrations, we evaluate the effect of visfatin on the genetic expression of MMP-1,TIMP-1 and ICAM-1 in human vascular endothelium.
Method:
HUVECs were incubated in vitro and treated with visfatin in 100ng/ml、200ng/ml、400ng/ml、800ng/ml levels for 24 hours respectively.Then total cellular RNA was extracted by Trizol method and the expression of MMP-1,TIMP-1 and ICAM-1 were detected in mRNA levels using RT-PCR method.
Results:
(1)Visfatin can increase the expression of MMP-1 mRNA significantly in a dose-dependent manner.
(2)Visfatin can reduce the expression of TIMP-1 mRNA significantly in a dose-dependent manner,and the ratio of MMP-1/TIMP-1 increased gradually with the increase of visfatin.
(3)Visfatin can increase the expression of ICAM-1 mRNA significantly in a dose-dependent manner.
Conclusion:
(1)The endothelium stimulated with visfatin can increase the expression of MMP-1 mRNA in a dose-dependent manner. And visfatin can down regulate the expression of TIMP-1 mRNA and result in the proportional imbalance of MMP-1/TIMP-1,which break the extracellular matrix synthesis and degradation balance finally.
(2)The endothelium stimulated with visfatin can increase the expression of ICAM-1 mRNA in a dose-dependent manner.
(3) Visfatin may be involved in the artery atherosclerotic disease through affecting the expression of MMP-1, TIMP-1 and ICAM-1 in human vascular endothelial cells.
动脉粥样硬化(atherosclerosis, AS)是各种心脑血管疾病最重要的危险因素,随着人民生活水平的提高及饮食结构的改变,肥胖以及与肥胖相关的疾病如糖尿病、高血压及高脂血症等的发病率也逐渐增加,并通过多种机制介导着AS的形成与发展。近年来的研究证明,肥胖患者体内过量的脂肪组织分泌的多种细胞因子在AS的发生中发挥着重要的作用。
内脏脂肪素(visfatin)是新发现的一种脂肪细胞因子,不仅与多种炎症疾病有关,还参与调节多种炎症因子的合成与分泌,能够促进单核细胞表达内皮细胞粘附分子1(ICAM-1)和内皮细胞表达血管内皮生长因子(VEGF)。已有研究发现内脏脂肪素在颈动脉和冠状动脉粥样硬化斑块中显著表达。提示内脏脂肪素可能作为炎症介质参与了动脉粥样硬化的发生和发展。基质金属蛋白酶1(MMP-1)及基质金属蛋白酶抑制物1(TIMP-1)和ICAM-1在炎症所致的内皮细胞损伤中具有重要的作用。
目的：
本研究通过观察不同浓度的内脏脂肪素对血管内皮细胞(vein endothelia cell, VEC) MMP-1、TIMP-1及ICAM-1基因表达的影响,在基因表达水平探讨内脏脂肪素损伤血管内皮细胞功能,诱发动脉粥样硬化和斑块破裂的相关机制。
研究方法：
采用体外培养人脐静脉内皮细胞(HUVEC)株,将传至3-6代时处于对数生长期的细胞作为研究对象。分别用浓度为100ng/ml、200ng/ml、400ng/ml、800ng/ml的内脏脂肪素干预细胞24小时,用Trizol法提取细胞总RNA,采用逆转录-聚合酶链反应(RT-PCR)技术半定量检测不同浓度内脏脂肪素刺激后内皮细胞MMP-1、TIMP-1和ICAM-1mRNA的表达。
结果：
(1)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的MMP-1mRNA显著增多,且呈浓度依赖性。
(2)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的TIMP-1mRNA呈浓度依赖性下降,MMP-1/TIMP-1比值随内脏脂肪素干预浓度的增高而逐渐升高。
(3)不同浓度的内脏脂肪素刺激内皮细胞24小时后,内皮细胞表达的ICAM-1mRNA水平显著升高,且其浓度越高,刺激内皮细胞表达ICAM-1mRNA的作用就越强。
结论：
(1)内脏脂肪素能够促进体外培养的人血管内皮细胞表达MMP-1,下调TIMP-1的表达,且呈剂量依赖性,MMP-1/TIMP-1的比例失衡,打破了细胞外基质合成与降解的平衡状态。
(2)内脏脂肪素促进了体外培养的人血管内皮细胞表达ICAM-1,并随着内脏脂肪素浓度的升高而表达增高,呈现剂量依赖性。
(3)内脏脂肪素可能作为炎症因子通过影响人血管内皮细胞MMP-1、TIMP-1及ICAM-1的表达参与了动脉粥样硬化性疾病的发生和发展。
Background:
As we know that atherosclerosis is the most important risk factor of cardiovascular and cardio-cerebrovascular disease. With the improvement of living standards and changing of eating habits, the incidence of obesity and obesity-related diseases such as diabetes, hypertension and hyperlipemia has gradually increased, and these diseases affect on the formation and development of atherosclerosis through various mechanisms. Recent studies have shown that several cytokines secreted by excess adipose tissue of obesity play an important role in the occurrence of atherosclerosis.
Visfatin is the most recently identified adipocytokine(known previously as pre-B cell colony enhancing factor, PBEF).Visfatin has not only associated with a variety of inflammatory diseases,but also can regulate the synthesis and secretion of inflammatory cytokine,stimulate the monoeyte releasing intereellular adhesion moleeule-1 and the endothelium releasing vascular endothelium growth factor. It has been found that visfatin expressed in carotid endarterectomy specimens and coronary artery plaques. This indicates that visfatin is not only an cytokine but also interact with atherosclerosis. MMP-1,TIMP-1 and ICAM-1 play an important role in the inflammation-induced endothelial cell injury.
Objective:
To investigate the mechanism of artherosclerosis and plaque disurptioninduced by dysfunction of vascular endothelial cell with visfatin in different concentrations, we evaluate the effect of visfatin on the genetic expression of MMP-1,TIMP-1 and ICAM-1 in human vascular endothelium.
Method:
HUVECs were incubated in vitro and treated with visfatin in 100ng/ml、200ng/ml、400ng/ml、800ng/ml levels for 24 hours respectively.Then total cellular RNA was extracted by Trizol method and the expression of MMP-1,TIMP-1 and ICAM-1 were detected in mRNA levels using RT-PCR method.
Results:
(1)Visfatin can increase the expression of MMP-1 mRNA significantly in a dose-dependent manner.
(2)Visfatin can reduce the expression of TIMP-1 mRNA significantly in a dose-dependent manner,and the ratio of MMP-1/TIMP-1 increased gradually with the increase of visfatin.
(3)Visfatin can increase the expression of ICAM-1 mRNA significantly in a dose-dependent manner.
Conclusion:
(1)The endothelium stimulated with visfatin can increase the expression of MMP-1 mRNA in a dose-dependent manner. And visfatin can down regulate the expression of TIMP-1 mRNA and result in the proportional imbalance of MMP-1/TIMP-1,which break the extracellular matrix synthesis and degradation balance finally.
(2)The endothelium stimulated with visfatin can increase the expression of ICAM-1 mRNA in a dose-dependent manner.
(3) Visfatin may be involved in the artery atherosclerotic disease through affecting the expression of MMP-1, TIMP-1 and ICAM-1 in human vascular endothelial cells.
引文
[1]Dnadona. Endothelium inflammation and diabetes [J]. Curt Diab ReP,2002,2(4): 311-315.
[2]Wang H, Wen Y, Mooney S, et al. Polan ML. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human preimplantation embryos[J]. Fertil Steril, 2003,80(Suppl2):736-742.
[3]Emonard H, Grimaud JA. Matrix metalloproteinases:A review[J]. Cell Mol Biol,1990, 36(2):131-153.
[4]Coconnier MH, Lievin V, Bernet-Camard MF, et al. Antibacterial effect of the adhering human lactobacillus acidophilus strain LB[J]. Antimicrob Agents Chemother,1997,41(5): 1046-1052.
[5]Bkaer AH, Edwdars DR, and Murphy G.. Metalloproteinase inhibitors:biologicalactions and therapeutic opportunities [J]. J Cell Sci,2002,115:3719-3727.
[6]Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science,2005,307(5708):426-430.
[7]Samal B, Sun Y, Stearns G, et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14:1431-1437.
[8]Kitania T, Okunoa S. Growth phase-dependent changes in the subcellular localization of Pre-B-cell colony-enhancing factor 1[J]. FEBS Letters,2003,544:74-78.
[9]McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and Characterization of Canine Pre-B-cell colony-enhancing factor[J]. Biochem Genet 2005,43:127-41.
[10]Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab.2007.6(5):363-375.
[11]Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription:NFAT and AP-1[J]. Oncogene,2001,20(19):2476-2489.
[12]Li Q, Verma I M. NF-kappaB regulation in the immune system[J]. Nat Rev Immunol,2002, 2(10):725-734.
[13]杨媚,杨刚毅,李伶,等.不同糖耐量个体血浆内脂素水平的变化.临床内分泌代谢 杂志[J],2006,22(3)：245-247.
[14]Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes[J].2010.118(2):75-80.
[15]Teoh H, Lovren F, Verma S. Vascular dysfunction:a Janus face of visfatin in diabetes Metabolism[J].2007Apr:56(4):459-461.
[16]Samal B, Sun Y, Stearns G,et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14:1431-1437.
[17]Moschen AR, Koser A, Enrich B, et al. Visfatin, an adipocytokine with and immunomodulating properties[J]. J Im-muno,2007,178(3):1748-1758.
[18]Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor(PBEF)/visfatin:a novel mediator of innate immunity[J]. J Leukoc Biol,2008,83:804-816.
[19]Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary possible role in inflammation and plaque destabilization[J]. Circulation,2007,115(8):972-980.
[20]Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs[M]. New York Oxford University Press,2000:1-10.
[21]Brinckerhoff CE, Matrisiam LM, et al. Matrix metalloproteinases:a tail of a frog that became a prince [J]. Nat Rev Mol Cell Biol,2002,3(3):207-214.
[22]汪俊军,顾振华,张春妮,等.脂蛋白(α)氧化和自身免疫与动脉粥样硬化的关系[J].医学研究生学报,2005,18(8)：740-742.
[23]McCawley LJ, Matrisian LM. Matrix metalloproteinases:they're not just for matrix anymore[J]. Curr Opin Cell Biol,2001,13(5):534-540.
[24]郭爱桃,韦立新,石怀银,等.基质金属蛋白酶-1与冠状动脉粥样硬化斑块破裂的关系[J].中华病理学杂志,2000,29(4)：263-266.
[25]Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable muman atheromatous plaques[J]. Circulation, 1999,99(19):2503-2509.
[26]Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 produetion via MAPK and PI3K/Akt signaling pathways:novel insights into visfatin-induced angiogenesis[J]. Cardiovasc Res,2008,78:356-365.
[27]Kim SR, Bae SK, Choi KS. et al. Visfatin promotes angiogenesis by activation of extra cellular signal-regulated kinase 1/2[J]. Biochem BioPhys Res Commun.2007,357: 150-156.
[28]Adya R, Tan BK. Chen J, Randeva HS. Nuelear Factor (kappa)B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 production and Activation[J]. Diabetes Care.2008,31:758-760.
[29]韩启德,文允缢.血管生物学[J].北京：北京医科大学协和医科大学联合出版社,1997,160-173.
[30]Vander A, Vander PT. Intercellular adhesion molecule-1[J]. Mo Med,1996,74(1): 13.
[31]Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhension molecule-1, E-selectin, P-selectin and thrombomodulin[J]. Artheroscler Thromb Vas Biol,1997,17(3):505.
[32]Valente AJ. Mechanisms in intimal monocyte-macrophage recruitment[J]. Circulation, 1992,86:Ⅲ20-25.
[33]Michael LD, Timothy AS. Lymphocyte functionassociated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cell[J]. Cell Bio,1988,107:321.
[34]Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells[J]. Biochim Biophys Acta.2008,1783(5):886-895.
[35]Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure[J]. Adv Med Sci.2008,53(1):32-36.
[36]Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond).2009,33(4): 465-472.
[1]Ross, R. Atherosclerosis-an inflammatory disease [J]. N Engl J Med,1999,340:115-126.
[2]Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J].Science,2005,307(5708):426-430.
[3]Samal B, Sun Y, Stearns G, et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14: 1431-1437.
[4]Ognjanovic S, BaoS, Yamamoto SY, et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes[J]. J Mol Endocrinol,2001,26:107-117.
[5]Rongvaux A, Shea RJ, Mulks MH, et al. pre-B-cell colony enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltrans-erase, a cytosolic enzyme involved in NAD biosynt hesis[J]. Eur J Immunol,2002,32: 3225-3234.
[6]Kitania T, Okunoa S, Growth phase-dependent changes in the subcellular localization of Pre-B-cell colony-enhancing factor 1[J]. FEBS Letters,2003,544:74-78.
[7]McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and Characterization of Pre-B-cell colony-enhancing factor[J]. Biochem Genet 2005,43:127-141.
[8]Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab.2007,6(5):363-375.
[9]Macian F, Lopez-Rodriguez C, Rao A.Partners in transcription:NFAT and AP-1[J]. Oncogene,2001,20(19):2476-2489.
[10]Li Q, Verma I M. NF-kappaB regulation in the immune system[J]. Nat Rev Immunol,2002, 2(10):725-734.
[11]Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 Adipocytes [J]. J Endocrinol,2005,185(3):R1-R8.
[12]Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocyte [J]. Am J Physiol Endocrinol Metab,2005,289(4): E586-590.
[13]Dominici FP, Argentino DP, Munoz MC, et al. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity[J]. Growth Horm IGF Res.2005,15(5):324-336.
[14]Haider D G, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin[J]. Diabetologia,2006,49(8):1909-1914.
[15]Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor [J]. FEBS Lett,2003,544(1/3): 74-78.
[16]Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental in flammation and clinical sepsis[J]. J Clin Invest,2004,113 (9): 1318-1327.
[17]van der Veer E, Nong Z, O'Neil C, et al. Pre-B-cell colony-enhancing factor regulates NAD+dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation[J]. Circ Res,2005,97(1):25-34.
[18]Filippatos TD, Randeva HS, Derdemezis CS, et al. VISFATIN/PBEF and Atherosclerosis-Related Diseases[J].Curr Vase Phar—macol.2010,8(1):12-28.
[19]Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009,71(2):202-207.
[20]Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary possible role in inflammation and plaque destabilization[J]. Circulation,2007,115(8):972-980.
[21]Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increase accumulation in obesity and a source of resistin and visfatin [J]. Diabetologia, 2006,49(4):744-747.
[22]Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury [J]. Am J Respir Crit Care Med,2005,171(4): 361-370.
[23]Jia SH,LiY, Parodo J. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sep-sis[J]. J C lin Invest,2004,113(9):1318-1327.
[24]Moschen AR, Koser A, Enrich B, et al. Visfatin, an adipocytokine with and immunomodulating properties[J]. J Im-muno.2007,178(3):1748-1758.
[25]Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin:a novel mediator of innate immunity [J]. J Leukoc Biol.2008,83:804-816.
[26]Baeuerle PA. The inducible transcription activator NF-kappaB:Regulation by distinct protein subunits[J]. Biochim Biophys Act,1991,1072(1):63-80.
[27]Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1 a cytokine-induced endo-thelial protein that binds to lymphocytes[J]. Cell, 1989,59(16):1203-1211.
[28]Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells[J]. Biochim Biophys Acta,2008,1783(5):886-895.
[29]Adya R, Tan BK, Chen J, et al. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells:role in visfatin-induced angiogenesis[J]. Atherosclerosis,2009,205(1):113-119.
[30]Wu KK. Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis[J]. Formos Med Assoc,1996,95(9):66.
[31]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type2 diabetes mellitus [J].Metabolism, 2007,56(4):451-458.
[32]Teoh H, Lovren F, Verma S. Vascular dysfunction:a Janus face of visfatin in diabetes[J] Metabolism,2007,56(4):459-461.
[33]Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 produetion via MAPK and PI3K/Akt signaling pathways:novel insights into visfatin-induced angiogenesis[J]. Cardiovasc Res,2008,78:356-365.
[34]Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extra cellular signal-regulated kinase 1/2[J]. Biochem BioPhys Res Commun.2007,357: 150-156.
[35]Adya R, Tan BK, Chen J. Nuelear Factor{kapppa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 production and Activation. Diabetes Care[J].2008,31:758-760.
[36]Adya R, Tan BK, Chen J. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells:its role in MMP-2/9 production and activation. Diabetes Care[J].2008, 31(4):758-760.
[37]Bae YH, Bae MK, Kim SR, et al. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis[J]. Biochem Biophys Res Commun.2009,379(2): 206-211.
[38]Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf).2008,69(6):878-884.
[39]Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes[J].2010,118(2):75-80.
[40]Tutta·P. The measurement by high resolution ultrasound of the intima-media thickness at the carotis comunis artery:early marker of atherosc lerosis[J]. Praxis(Bern1994),2007,96(21): 851-857.
[41]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endot helial function in patients with type 2 diabetes mellitus[J]. Metabolism, 2007,56(4):451-458.
[42]Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans[J]. Diabetes,2005,4(10):2911-2916.
[43]Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding [J]. J Clin Endocrinol Metab, 2006,91(4):1578-1581.
[44]Chen MP, Chung FM,Chang DM, et al. Elevated plasma level of visfatin/Pre-B-cell colony-enhancing factor in patients with type 2diabetes mellitus[J]. J Clin Endocrinol Metab,2006,91(1):295-299.
[45]Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid p rofile[J]. Pflug Arch Eur J Physi,2007,454(6):971-976.
[46]Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA exp ression in humans[J]. Diabetes,2005,54(10):2911-2916.
[47]Klting N, Klting I. Visfatin:gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats[J]. B iochem B iophys Res Commun, 2005,332(4):1070-1072.
[48]Oita RC, Ferdinando D, Wilson S, et al. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NFkB-dependent manner. Pflugers Arch[J].2010,459(4):619-630.
[49]Milne GL, Musiek ES, Morrow J D. F2-isoprostanes as markers of oxidative stress in vivo: an overview[J]. Bio markers,2005,10(Suppl 1):S10-23.
[50]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus[J]. Metabolism, 2007,56(4):451-458.
[2]Wang H, Wen Y, Mooney S, et al. Polan ML. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human preimplantation embryos[J]. Fertil Steril, 2003,80(Suppl2):736-742.
[3]Emonard H, Grimaud JA. Matrix metalloproteinases:A review[J]. Cell Mol Biol,1990, 36(2):131-153.
[4]Coconnier MH, Lievin V, Bernet-Camard MF, et al. Antibacterial effect of the adhering human lactobacillus acidophilus strain LB[J]. Antimicrob Agents Chemother,1997,41(5): 1046-1052.
[5]Bkaer AH, Edwdars DR, and Murphy G.. Metalloproteinase inhibitors:biologicalactions and therapeutic opportunities [J]. J Cell Sci,2002,115:3719-3727.
[6]Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science,2005,307(5708):426-430.
[7]Samal B, Sun Y, Stearns G, et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14:1431-1437.
[8]Kitania T, Okunoa S. Growth phase-dependent changes in the subcellular localization of Pre-B-cell colony-enhancing factor 1[J]. FEBS Letters,2003,544:74-78.
[9]McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and Characterization of Canine Pre-B-cell colony-enhancing factor[J]. Biochem Genet 2005,43:127-41.
[10]Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab.2007.6(5):363-375.
[11]Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription:NFAT and AP-1[J]. Oncogene,2001,20(19):2476-2489.
[12]Li Q, Verma I M. NF-kappaB regulation in the immune system[J]. Nat Rev Immunol,2002, 2(10):725-734.
[13]杨媚,杨刚毅,李伶,等.不同糖耐量个体血浆内脂素水平的变化.临床内分泌代谢 杂志[J],2006,22(3)：245-247.
[14]Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes[J].2010.118(2):75-80.
[15]Teoh H, Lovren F, Verma S. Vascular dysfunction:a Janus face of visfatin in diabetes Metabolism[J].2007Apr:56(4):459-461.
[16]Samal B, Sun Y, Stearns G,et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14:1431-1437.
[17]Moschen AR, Koser A, Enrich B, et al. Visfatin, an adipocytokine with and immunomodulating properties[J]. J Im-muno,2007,178(3):1748-1758.
[18]Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor(PBEF)/visfatin:a novel mediator of innate immunity[J]. J Leukoc Biol,2008,83:804-816.
[19]Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary possible role in inflammation and plaque destabilization[J]. Circulation,2007,115(8):972-980.
[20]Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs[M]. New York Oxford University Press,2000:1-10.
[21]Brinckerhoff CE, Matrisiam LM, et al. Matrix metalloproteinases:a tail of a frog that became a prince [J]. Nat Rev Mol Cell Biol,2002,3(3):207-214.
[22]汪俊军,顾振华,张春妮,等.脂蛋白(α)氧化和自身免疫与动脉粥样硬化的关系[J].医学研究生学报,2005,18(8)：740-742.
[23]McCawley LJ, Matrisian LM. Matrix metalloproteinases:they're not just for matrix anymore[J]. Curr Opin Cell Biol,2001,13(5):534-540.
[24]郭爱桃,韦立新,石怀银,等.基质金属蛋白酶-1与冠状动脉粥样硬化斑块破裂的关系[J].中华病理学杂志,2000,29(4)：263-266.
[25]Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable muman atheromatous plaques[J]. Circulation, 1999,99(19):2503-2509.
[26]Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 produetion via MAPK and PI3K/Akt signaling pathways:novel insights into visfatin-induced angiogenesis[J]. Cardiovasc Res,2008,78:356-365.
[27]Kim SR, Bae SK, Choi KS. et al. Visfatin promotes angiogenesis by activation of extra cellular signal-regulated kinase 1/2[J]. Biochem BioPhys Res Commun.2007,357: 150-156.
[28]Adya R, Tan BK. Chen J, Randeva HS. Nuelear Factor (kappa)B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 production and Activation[J]. Diabetes Care.2008,31:758-760.
[29]韩启德,文允缢.血管生物学[J].北京：北京医科大学协和医科大学联合出版社,1997,160-173.
[30]Vander A, Vander PT. Intercellular adhesion molecule-1[J]. Mo Med,1996,74(1): 13.
[31]Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhension molecule-1, E-selectin, P-selectin and thrombomodulin[J]. Artheroscler Thromb Vas Biol,1997,17(3):505.
[32]Valente AJ. Mechanisms in intimal monocyte-macrophage recruitment[J]. Circulation, 1992,86:Ⅲ20-25.
[33]Michael LD, Timothy AS. Lymphocyte functionassociated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cell[J]. Cell Bio,1988,107:321.
[34]Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells[J]. Biochim Biophys Acta.2008,1783(5):886-895.
[35]Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure[J]. Adv Med Sci.2008,53(1):32-36.
[36]Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond).2009,33(4): 465-472.
[1]Ross, R. Atherosclerosis-an inflammatory disease [J]. N Engl J Med,1999,340:115-126.
[2]Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J].Science,2005,307(5708):426-430.
[3]Samal B, Sun Y, Stearns G, et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor[J]. Mol Cell Biol,1994,14: 1431-1437.
[4]Ognjanovic S, BaoS, Yamamoto SY, et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes[J]. J Mol Endocrinol,2001,26:107-117.
[5]Rongvaux A, Shea RJ, Mulks MH, et al. pre-B-cell colony enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltrans-erase, a cytosolic enzyme involved in NAD biosynt hesis[J]. Eur J Immunol,2002,32: 3225-3234.
[6]Kitania T, Okunoa S, Growth phase-dependent changes in the subcellular localization of Pre-B-cell colony-enhancing factor 1[J]. FEBS Letters,2003,544:74-78.
[7]McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and Characterization of Pre-B-cell colony-enhancing factor[J]. Biochem Genet 2005,43:127-141.
[8]Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab.2007,6(5):363-375.
[9]Macian F, Lopez-Rodriguez C, Rao A.Partners in transcription:NFAT and AP-1[J]. Oncogene,2001,20(19):2476-2489.
[10]Li Q, Verma I M. NF-kappaB regulation in the immune system[J]. Nat Rev Immunol,2002, 2(10):725-734.
[11]Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 Adipocytes [J]. J Endocrinol,2005,185(3):R1-R8.
[12]Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocyte [J]. Am J Physiol Endocrinol Metab,2005,289(4): E586-590.
[13]Dominici FP, Argentino DP, Munoz MC, et al. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity[J]. Growth Horm IGF Res.2005,15(5):324-336.
[14]Haider D G, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin[J]. Diabetologia,2006,49(8):1909-1914.
[15]Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor [J]. FEBS Lett,2003,544(1/3): 74-78.
[16]Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental in flammation and clinical sepsis[J]. J Clin Invest,2004,113 (9): 1318-1327.
[17]van der Veer E, Nong Z, O'Neil C, et al. Pre-B-cell colony-enhancing factor regulates NAD+dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation[J]. Circ Res,2005,97(1):25-34.
[18]Filippatos TD, Randeva HS, Derdemezis CS, et al. VISFATIN/PBEF and Atherosclerosis-Related Diseases[J].Curr Vase Phar—macol.2010,8(1):12-28.
[19]Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009,71(2):202-207.
[20]Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary possible role in inflammation and plaque destabilization[J]. Circulation,2007,115(8):972-980.
[21]Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increase accumulation in obesity and a source of resistin and visfatin [J]. Diabetologia, 2006,49(4):744-747.
[22]Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury [J]. Am J Respir Crit Care Med,2005,171(4): 361-370.
[23]Jia SH,LiY, Parodo J. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sep-sis[J]. J C lin Invest,2004,113(9):1318-1327.
[24]Moschen AR, Koser A, Enrich B, et al. Visfatin, an adipocytokine with and immunomodulating properties[J]. J Im-muno.2007,178(3):1748-1758.
[25]Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin:a novel mediator of innate immunity [J]. J Leukoc Biol.2008,83:804-816.
[26]Baeuerle PA. The inducible transcription activator NF-kappaB:Regulation by distinct protein subunits[J]. Biochim Biophys Act,1991,1072(1):63-80.
[27]Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1 a cytokine-induced endo-thelial protein that binds to lymphocytes[J]. Cell, 1989,59(16):1203-1211.
[28]Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells[J]. Biochim Biophys Acta,2008,1783(5):886-895.
[29]Adya R, Tan BK, Chen J, et al. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells:role in visfatin-induced angiogenesis[J]. Atherosclerosis,2009,205(1):113-119.
[30]Wu KK. Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis[J]. Formos Med Assoc,1996,95(9):66.
[31]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type2 diabetes mellitus [J].Metabolism, 2007,56(4):451-458.
[32]Teoh H, Lovren F, Verma S. Vascular dysfunction:a Janus face of visfatin in diabetes[J] Metabolism,2007,56(4):459-461.
[33]Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 produetion via MAPK and PI3K/Akt signaling pathways:novel insights into visfatin-induced angiogenesis[J]. Cardiovasc Res,2008,78:356-365.
[34]Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extra cellular signal-regulated kinase 1/2[J]. Biochem BioPhys Res Commun.2007,357: 150-156.
[35]Adya R, Tan BK, Chen J. Nuelear Factor{kapppa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 production and Activation. Diabetes Care[J].2008,31:758-760.
[36]Adya R, Tan BK, Chen J. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells:its role in MMP-2/9 production and activation. Diabetes Care[J].2008, 31(4):758-760.
[37]Bae YH, Bae MK, Kim SR, et al. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis[J]. Biochem Biophys Res Commun.2009,379(2): 206-211.
[38]Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf).2008,69(6):878-884.
[39]Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes[J].2010,118(2):75-80.
[40]Tutta·P. The measurement by high resolution ultrasound of the intima-media thickness at the carotis comunis artery:early marker of atherosc lerosis[J]. Praxis(Bern1994),2007,96(21): 851-857.
[41]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endot helial function in patients with type 2 diabetes mellitus[J]. Metabolism, 2007,56(4):451-458.
[42]Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans[J]. Diabetes,2005,4(10):2911-2916.
[43]Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding [J]. J Clin Endocrinol Metab, 2006,91(4):1578-1581.
[44]Chen MP, Chung FM,Chang DM, et al. Elevated plasma level of visfatin/Pre-B-cell colony-enhancing factor in patients with type 2diabetes mellitus[J]. J Clin Endocrinol Metab,2006,91(1):295-299.
[45]Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid p rofile[J]. Pflug Arch Eur J Physi,2007,454(6):971-976.
[46]Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA exp ression in humans[J]. Diabetes,2005,54(10):2911-2916.
[47]Klting N, Klting I. Visfatin:gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats[J]. B iochem B iophys Res Commun, 2005,332(4):1070-1072.
[48]Oita RC, Ferdinando D, Wilson S, et al. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NFkB-dependent manner. Pflugers Arch[J].2010,459(4):619-630.
[49]Milne GL, Musiek ES, Morrow J D. F2-isoprostanes as markers of oxidative stress in vivo: an overview[J]. Bio markers,2005,10(Suppl 1):S10-23.
[50]Takebayashi K, Suet sugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus[J]. Metabolism, 2007,56(4):451-458.